171 related articles for article (PubMed ID: 34264023)
1. HO-1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy.
Akaishi R; Fujishima F; Ishida H; Tsunokake J; Yamauchi T; Gokon Y; Ueki S; Fukutomi T; Okamoto H; Takaya K; Sato C; Taniyama Y; Nakamura T; Nakaya N; Kamei T; Sasano H
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1477. PubMed ID: 34264023
[TBL] [Abstract][Full Text] [Related]
2. Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma.
Akaishi R; Fujishima F; Ishida H; Tsunokake J; Yamauchi T; Gokon Y; Ueki S; Fukutomi T; Okamoto H; Takaya K; Sato C; Taniyama Y; Nakamura T; Nakaya N; Kamei T; Sasano H
Esophagus; 2022 Jul; 19(3):436-443. PubMed ID: 34999996
[TBL] [Abstract][Full Text] [Related]
3. NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis.
Gao Y; Wan L; Li M; Wang B; Ma Y
Int J Biol Markers; 2023 Dec; 38(3-4):174-184. PubMed ID: 37312528
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
[TBL] [Abstract][Full Text] [Related]
5. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.
Aiko S; Yoshizumi Y; Ishizuka T; Sakano T; Kumano I; Sugiura Y; Maehara T
Dis Esophagus; 2007; 20(2):94-101. PubMed ID: 17439591
[TBL] [Abstract][Full Text] [Related]
6. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
[TBL] [Abstract][Full Text] [Related]
7. Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment.
Shen H; Yang Y; Xia S; Rao B; Zhang J; Wang J
Dis Esophagus; 2014; 27(7):685-92. PubMed ID: 24028437
[TBL] [Abstract][Full Text] [Related]
8. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
[TBL] [Abstract][Full Text] [Related]
9. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
10. Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study.
Cavallin F; Alfieri R; Scarpa M; Cagol M; Ruol A; Fassan M; Rugge M; Ancona E; Castoro C
BMC Surg; 2017 May; 17(1):49. PubMed ID: 28464907
[TBL] [Abstract][Full Text] [Related]
11. Completely Resectable (cT1-2) Esophageal Squamous Cell Carcinoma with Minimal Lymph Node Involvement (cN1): Is Neoadjuvant Chemoradiation Therapy the Only Viable Treatment Option?
Yang YH; Park BJ; Kim HE; Kim H; Kim DJ
Ann Surg Oncol; 2024 Apr; 31(4):2490-2498. PubMed ID: 38153644
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of metastatic lymph node number and ratio in oesophageal squamous cell carcinoma patients with or without neoadjuvant chemoradiation.
Chien HC; Chen HS; Wu SC; Hsu PK; Liu CY; Wang BY; Shih CH; Liu CC
Eur J Cardiothorac Surg; 2016 Aug; 50(2):337-43. PubMed ID: 26893382
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Li CY; Huang PM; Chu PY; Chen PM; Lin MW; Kuo SW; Lee JM
Biomed Res Int; 2016; 2016():6423297. PubMed ID: 27777949
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Nabeya Y; Ochiai T; Matsubara H; Okazumi S; Shiratori T; Shuto K; Aoki T; Miyazaki S; Gunji Y; Uno T; Ito H; Shimada H
Dis Esophagus; 2005; 18(6):388-97. PubMed ID: 16336610
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Nrf2/HO-1 expression and its correlation with occurrence in esophageal squamous cell carcinoma.
Gao Y; Li M; Wang B; Ma Y
Genes Genomics; 2023 Jun; 45(6):723-739. PubMed ID: 37043130
[TBL] [Abstract][Full Text] [Related]
17. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
18. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study.
Hagens ERC; van Berge Henegouwen MI; van Sandick JW; Cuesta MA; van der Peet DL; Heisterkamp J; Nieuwenhuijzen GAP; Rosman C; Scheepers JJG; Sosef MN; van Hillegersberg R; Lagarde SM; Nilsson M; Räsänen J; Nafteux P; Pattyn P; Hölscher AH; Schröder W; Schneider PM; Mariette C; Castoro C; Bonavina L; Rosati R; de Manzoni G; Mattioli S; Garcia JR; Pera M; Griffin M; Wilkerson P; Chaudry MA; Sgromo B; Tucker O; Cheong E; Moorthy K; Walsh TN; Reynolds J; Tachimori Y; Inoue H; Matsubara H; Kosugi SI; Chen H; Law SYK; Pramesh CS; Puntambekar SP; Murthy S; Linden P; Hofstetter WL; Kuppusamy MK; Shen KR; Darling GE; Sabino FD; Grimminger PP; Meijer SL; Bergman JJGHM; Hulshof MCCM; van Laarhoven HWM; Mearadji B; Bennink RJ; Annema JT; Dijkgraaf MGW; Gisbertz SS
BMC Cancer; 2019 Jul; 19(1):662. PubMed ID: 31272485
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Kakeji Y; Kono K; Kitagawa Y; Takeuchi H
Esophagus; 2024 Jan; 21(1):2-10. PubMed ID: 37999900
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
